Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma and other plasma cell disorders

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4850-4860

  Bae, Jooeun ^a,c   Smith, Robert ^a,c   Daley, John ^a,c   Mimura, Naoya ^a,c   Tai, Yu Tzu ^a,c   Anderson, Kenneth C ^a,c   Munshi, Nikhil C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCYLLEUCYLVALYLGLYCYLLEUCYLISOLEUCYLPHENYLALANYLALANYLVALINE; HLA A2 ANTIGEN; PEPTIDE DERIVATIVE; SERYLLEUCYLPHENYLALANYLVALYLLEUCYLGLYCYLLEUCYLPHENYLALANYLLEUCINE; TUMOR ANTIGEN; TYROSYLISOLEUCYLSERYLPROLYLTRYPTOPHANYLISOLEUCYLLEUCYLALANYLVALINE; TYROSYLLEUCYLPHENYLALANYLPROLYLGLUTAMINYLLEUCYLISOLEUCYLSERYLVALINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; UPREGULATION;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; HLA-A2 ANTIGEN; HUMANS; MULTIPLE MYELOMA; PEPTIDE FRAGMENTS; PEPTIDES; SYNDECAN-1; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION FACTORS; VACCINES, SUBUNIT;

EID: 84865786752     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2776     Document Type: Article

References (56)

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
2. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011;6:249-74.
3. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117:4696-700.
4. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol 2007;3:299-306.
5. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010;22:144-54.
6. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
7. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-94.
8. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
9. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-11.
10. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood 2010;116:250-3.
11. Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, et al. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science 1990;247:1581-4.
12. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-7.
13. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001;107:881-91.
14. Mori K. Frame switch splicing and regulated intramembrane proteolysis: key words to understand the unfolded protein response. Traffic 2003;4:519-28.
15. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103:3175-84.
16. Wolowiec D, Dybko J, Wrobel T, Urbaniak-Kujda D, Jazwiec B, Tomaszewska-Toporska B, et al. Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm 2006;2006:42394-9.
17. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989;1:27-35.
18. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002;100:610-7.
19. Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 2008;25:149-59.
20. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-24.
21. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-84.
22. Murphy JJ, Hobby P, Vilarino-Varela J, Bishop B, Iordanidou P, Sutton BJ, et al. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem J 2002;361:431-6.
23. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002;39:1-8.
24. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37.
25. Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC, et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 2011;25:1610-9.
26. Bae J, Tai YT, Anderson KC, Munshi NC. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol 2011;155:349-61.
27. Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, et al. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol 2012;157:687-701.
28. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450-7.
29. Bae J, Martinson JA, Klingemann HG. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol 2004;227:38-50.
30. Toujas L, Delcros JG, Diez E, Gervois N, Semana G, Corradin G, et al. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology 1997;91:635-42.
31. Angulo R, Fulcher DA. Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression. Cytometry 1998;34:143-51.
32. Roden MM, Lee KH, Panelli MC, Marincola FM. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999;226:29-41.
33. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 2002;259:95-110.
34. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009;1:548-51.
35. Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011;117:1311-4.
36. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 2000;96:2528-36.
37. Lotz C, Mutallib SA, Oehlrich N, Liewer U, Ferreira EA, Moos M, et al. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol 2005;175:1301-9.
38. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;160:348-58.
39. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 2005;90:1324-32.
40. May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007;13:4547-55.
41. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000;192:1105-13.
42. Powell DJ Jr, Rosenberg SA. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 2004;27:36-47.
43. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
44. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009;15:7036-44.
45. Thompson LW, Garbee CF, Hibbitts S, Brinckerhoff LH, Pierce RA, Chianese-Bullock KA, et al. Competition among peptides in melanoma vaccines for binding to MHC molecules. J Immunother 2004;27:425-31.
46. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
47. Mullins DW, Engelhard VH. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol 2006;176:4535-42.
48. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
49. Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009;15:2166-73.
50. Giannopoulos K, Dmoszynska A, Kowal M, Rolinski J, Gostick E, Price DA, et al. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 2010;24:798-805.
51. Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother 2011;60:161-71.
52. Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, et al. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol 2007;178:7730-7.
53. Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P, et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011;25:161-8.
54. LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-90.
55. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
56. Kitamura H, Sedlik C, Jacquet A, Zaragoza B, Dusseaux M, Premel V, et al. Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm. J Immunol 2010;185:892-901.